Deals: Page
-
AstraZeneca sells off dermatology drug rights to LEO Pharma
The British drugmaker also terminated a prior deal granting Valeant European rights to a psoriasis treatment, licensing those rights to LEO instead.
By Ned Pagliarulo • July 1, 2016 -
Boston startup secures $51.5 million in race for next-gen integrin technology
GlaxoSmithKline, Pfizer and AbbVie are among the backers betting integrin-pioneer Tim Springer's research will pay off.
By Edwin Lopez • June 30, 2016 -
Teva, Allergan sell off more drugs in quest for approval of generics deal
Mayne Pharma, an Australian company, will pay $652 million for 42 generic drugs currently held by the two companies.
By Nicole Gray • June 29, 2016 -
Dr. Reddy's breaks off marketing partnership with Glaxo
The Indian drugmaker plans to expand its presence in a number of emerging markets covered under the 2009 agreement.
By Nicole Gray • June 28, 2016 -
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
The Swiss pharma giant will partner with Xencor to develop two bi-specific antibodies for treatment of blood cancers.
By Ned Pagliarulo • June 28, 2016 -
Courtesy of Sanofi
Sanofi, Boehringer trade business units in $25 billion swap
Under the agreement, Sanofi will get Boehringer's consumer healthcare business in return for sending its Merial animal-health unit to Boehringer.
By Ned Pagliarulo • June 27, 2016 -
Takeda hands back two developmental drugs to Amgen
Under a 2008 collaboration deal, Takeda was granted rights to 13 Amgen molecules in the Japanese market.
By Nicole Gray • June 27, 2016 -
Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug
Selecta is the sixth Massachusetts-based biotech to go public this year.
By Nicole Gray • June 23, 2016 -
Celgene puts up $50 million to partner with four NCI cancer centers
The four high-profile centers have banded together to create a unified cancer research group
By Nicole Gray • June 23, 2016 -
Austin biotech Savara adds two lung drugs in deal for Serendex
Savara raised $20 million in March to advance its lead drug, an inhaled antibiotic, into Phase 3 testing.
By Nicole Gray • June 22, 2016 -
Teva, Allergan continue to shed assets with $586 million sale to Impax
The Israeli drugmaker has been selling off non-core drugs as it works to clear regulatory review for its $41 billion acquisition of Allergan's generics unit.
By Ned Pagliarulo • June 21, 2016 -
Venture funding for UK biotechs hits new high
But the number of deals dropped last year, continuing a downward trend from 2013.
By Nicole Gray • June 17, 2016 -
NYC-based Rgenix raises $33 million to advance cancer immunotherapy
The biotech hopes to start Phase 1 testing on the drug this fall.
By Nicole Gray • June 15, 2016 -
Teva hands back global rights for heart drug to Australian Mesoblast
Mesoblast will now have to fund Phase 3 development of the drug without a major partner.
By Nicole Gray • June 15, 2016 -
Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT
Aegerion had laid off 25% of its staff earlier this year and pleaded guilty to misbranding its cholesterol drug last month.
By Ned Pagliarulo • June 15, 2016 -
Shire buys rights to Pfizer bowel disease drug
The drug has returned positive data in early- and mid-stage trials, and a phase 3 is expected to begin after consultation with regulators.
By Ned Pagliarulo • June 14, 2016 -
Former Dendreon CEO leads Alpine Immune to $48 million financing
While at Dendreon, Mitch Gold oversaw development of the cancer cell therapy Provenge, which failed to live up to expectations following approval in 2010.
By Ned Pagliarulo • June 14, 2016 -
Dr. Reddy's snaps up eight generics from Teva for $350 million
Teva is divesting assets in order to win U.S. approval for its $40.5 billion acquisition of Allergan's generics business.
By Nicole Gray • June 14, 2016 -
Walgreens kills Theranos partnership, will close blood testing centers
The drugstore chain's decision is another huge blow to the controversial blood testing company.
By Randy Lilleston • June 13, 2016 -
Valeant weighs sale of Egyptian drug company
Last year, Valeant acquired Amoun Pharmaceuticals for $800 million via purchase of Mercury Holdings.
By Nicole Gray • June 13, 2016 -
Montgomery County Planning Commission
Merck acquires Afferent for $500M plus milestones
The deal gives Merck access to two promising treatments for chronic cough.
By Randy Lilleston • June 13, 2016 -
Report: Oncology drove record pharma dealmaking in 2015
Records were set last year for venture funding raised for drug companies, as well as upfront dollar value of licensing deals for R&D-stage assets, according to the new report.
By Ned Pagliarulo • June 9, 2016 -
Courtesy of Sanofi
Sanofi boosts takeover pressure, names Medivation board candidates
The move, if successful, would put in place a board that would be friendly to purchase by Sanofi, which Medivation so far has resisted.
By Randy Lilleston • June 9, 2016 -
AstraZeneca continues to shed rights to gout drug
Germany-based Grünenthal will pay up to $230 million for European and Latin American rights to Zurampic, a month after AstraZeneca sold U.S. rights to Ironwood.
By Nicole Gray • June 3, 2016 -
Swiss biotech AC Immune readies US IPO
Regulatory filings indicated the company hopes to raise up to $50 million, which it plans to use to advance its Alzheimer's drug.
By Nicole Gray • June 2, 2016
Previous
